Clinical trialNCT06682793RecruitingPhase 1/PHASE2Interventional

A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

SponsorA2 Biotherapeutics Inc.Enrollment240CRCCancerColon CancerColorectal AdenocarcinomaColorectal CancerHNSCC+11 more conditions

View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

John Welch, MD, PhD
A2 Biotherapeutics
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

10 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Banner Md Anderson Cancer Center
Gilbert, Arizona, United States
Matthew Ulrickson, MD
Recruiting
Ucsd Moores Cancer Center
La Jolla, California, United States
Rebecca Shatsky, MD
Recruiting
Ucla Medical Center
Los Angeles, California, United States
Deborah Wong, MD
Recruiting
Mayo Clinic
Jacksonville, Florida, United States
Yanyan Lou, MD
Recruiting
Moffitt Cancer Center
Tampa, Florida, United States
Kedar Kirtane, MD
Recruiting
Mayo Clinic
Rochester, Minnesota, United States
Harry E. Fuentes Bayne, MD
Recruiting
Washington University
St Louis, Missouri, United States
Patrick Grierson, M.D., Ph.D.
Recruiting
Nyu Langone Health
New York, New York, United States
Salman Punekar, MD
Recruiting
the Ohio State University
Columbus, Ohio, United States
Kai He, MD, PhD
Recruiting
Fred Hutch Cancer Center
Seattle, Washington, United States
Jennifer Specht, MD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 22 May 2025
Primary completion: 31 Mar 2029
Completion: 31 Mar 2030
Last update posted: 9 Sept 2025
Registered enrollment: 240
Registry id: NCT06682793

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.